Savara Inc (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Savara Inc (NASDAQ:SVRA) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $9.86.

Several equities analysts have commented on the stock. Wells Fargo & Company began coverage on shares of Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price on the stock. HC Wainwright reduced their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Finally, Evercore ISI reissued an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th.

Insider Transactions at Savara

In other news, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the transaction, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. The trade was a 3.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.13% of the stock is owned by insiders.

Hedge Funds Weigh In On Savara

A number of hedge funds have recently bought and sold shares of SVRA. Cibc World Markets Corp purchased a new position in Savara in the 4th quarter worth about $33,000. XTX Topco Ltd purchased a new position in Savara in the 4th quarter worth about $34,000. Ameriprise Financial Inc. purchased a new position in Savara in the 4th quarter worth about $37,000. KLP Kapitalforvaltning AS purchased a new position in Savara in the 4th quarter worth about $41,000. Finally, Hsbc Holdings PLC purchased a new position in Savara in the 4th quarter worth about $48,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Price Performance

Shares of Savara stock opened at $2.80 on Thursday. Savara has a twelve month low of $2.59 and a twelve month high of $5.70. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a 50-day simple moving average of $2.97 and a two-hundred day simple moving average of $3.57. The stock has a market capitalization of $480.54 million, a price-to-earnings ratio of -6.51 and a beta of 0.63.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.